SCHEMBL7230355

SCHEMBL7230355

Cn1cc(C(=O)O)c(=O)c2cc3cc(F)c(Cl)cc3nc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.39
CYP2C9 P11712 2/20 0.39
ATP6V1B2 P21281 1/20 0.39
TBXA2R P21731 1/20 0.39
EDNRA P25101 1/20 0.39
TARBP2 Q15633 1/20 0.39
DPP4 P27487 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
KEAP1 Q14145 1/20 0.35
NFE2L2 Q16236 1/20 0.35
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
ABCC4 O15439 1/20 0.34
PKM P14618 1/20 0.34
PTGS1 P23219 1/20 0.34
TOP2A P11388 1/20 0.34
TOP2B Q02880 1/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
DRD3 P35462 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6605949 0.90 LMNA (0.41) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL7235145 0.86 CYP2C9 (0.37) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL9532760 0.85 EGLN1 (0.32) EGLN1
SCHEMBL9775979 0.85 TOP2A (0.37) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL7229905 0.85 LMNA (0.55) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL9775919 0.85 LMNA (0.43) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL9532522 0.85 BAZ2B (0.48) LMNAKMT2AKDM4EALDH1A1POLB
SCHEMBL6603661 0.82 DPP4 (0.53) LMNACYP2C9DPP4ABCC4TOP2A
SCHEMBL1444489 0.81 KEAP1 (0.49) LMNACYP2C9ATP6V1B2TBXA2REDNRA
SCHEMBL9785206 0.81 LMNA (0.44) LMNACYP2C9ATP6V1B2TBXA2REDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0379413-B1 1,8-Benzonaphthyridine derivatives, their production and compositions containing them BELLON LABOR SA ROGER (FR) 1993-12-22 EP claimed
US-4990515-A Chemical intermediates RHONE-POULENC SANTE (FR) 1991-02-05 US claimed
US-6548506-B2 1-substituted,3-carboxy,7-fluoro,8-disubstituted amino-1,4-dihydrobenzo(b)(1,8)naphthyridin-4-ones; Useful as antimicrobial agents; topical antibiotic for wounds AVENTIS PHARMA S.A. (FR) 2003-04-15 US disclosed
US-20020037891-A1 Novel benzo[1,8]naphthyridine derivatives, their preparation and pharmaceutical compositions which comprise them AVENTIS PHARMA S.A. (FR) 2002-03-28 US disclosed
US-5053509-A Microbiocides; AIDS LABORATOIRE ROGER BELLON (FR) 1991-10-01 US disclosed
US-5004745-A Benzo[1,8]naphthyridine derivatives, their preparation and the compositions which contain them LABORATOIRE ROGER BELLON (FR) 1991-04-02 US disclosed
US-4990515-A Chemical intermediates RHONE-POULENC SANTE (FR) 1991-02-05 US disclosed
US-4970213-A Benzo(1,8)naphthyridine derivatives as intermediates RHONE-POULENC SANTE (FR) 1990-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037891-A1 Novel benzo[1,8]naphthyridine derivatives, their preparation and pharmaceutical compositions which comprise them ABCB11, NDUFA9, NDUFC1 LMNA 1363/4885CYP2C9 111/4885ATP6V1B2 1314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.